Home » Stocks » Oragenics

Oragenics Inc. (OGEN)

Stock Price: $1.07 USD -0.06 (-5.31%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Pre-market: $1.06 -0.01 (-0.94%) Aug 7, 8:33 AM

Stock Price Chart

Key Info

Market Cap 59.24M
Revenue (ttm) n/a
Net Income (ttm) -17.43M
Shares Out 60.90M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $1.07
Previous Close $1.13
Change ($) -0.06
Change (%) -5.31%
Day's Open -
Day's Range 1.06 - 1.11
Day's Volume 2,894,160
52-Week Range 0.35 - 2.09

More Stats

Market Cap 59.24M
Enterprise Value 45.73M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 60.90M
Float 35.09M
EPS (basic) -0.37
EPS (diluted) -0.38
FCF / Share -0.32
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.00M
Short Ratio 0.32
Short % of Float 6.83%
Beta 0.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.21
Revenue n/a
Operating Income -17.72M
Net Income -17.43M
Free Cash Flow -14.64M
Net Cash 13.51M
Net Cash / Share 0.24
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -47.25%
ROE -82.93%
ROIC -8,876.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.50*
Low
2.50
Current: $1.07
High
2.50
Target: 2.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-----0.941.031.331.441.31
Revenue Growth------8.94%-22.49%-7.8%10.35%-
Gross Profit-----0.570.690.450.730.40
Operating Income-15.88-9.99-6.72-8.54-11.78-5.82-16.21-12.43-7.35-7.90
Net Income-15.57-9.91-6.73-7.01-11.71-5.79-16.07-13.09-7.68-7.81
Shares Outstanding42.2813.044.934.463.673.622.881.770.570.55
Earnings Per Share-0.37-0.87-1.37-1.57-3.20-1.60-5.60-7.40-13.40-14.20
Operating Cash Flow-13.01-9.08-6.36-7.08-5.19-5.56-6.76-5.21-5.49-6.45
Capital Expenditures-0.03-0.12--0.02-0.10-0.11-0.02-0.01--0.09
Free Cash Flow-13.04-9.20-6.36-7.10-5.29-5.67-6.78-5.22-5.49-6.54
Cash & Equivalents18.2720.216.174.085.0810.4516.289.990.440.61
Total Debt0.980.120.080.070.060.060.060.057.552.10
Net Cash / Debt17.2920.086.094.015.0210.3816.219.94-7.12-1.49
Assets19.7522.057.214.315.7811.1316.8310.491.271.73
Liabilities2.521.170.901.341.050.800.991.269.453.63
Book Value17.2320.886.322.974.7310.3415.849.23-8.18-1.90
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oragenics Inc.
Country United States
Employees 7
CEO Alan F. Joslyn

Stock Information

Ticker Symbol OGEN
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: OGEN

Description

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.